Hemodialysis-resistant Hypertension: Control with an Orally Active Inhibitor of Angiotensin-converting Enzyme

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 1979 May 1

PMID 219011

Citations 9

Authors

E D Vaughan Jr

R M Carey

C R Ayers

M J Peach

Affiliations

Soon will be listed here.

Abstract

In two patients with end stage renal disease and dialysis-resistant hypertension, the orally active inhibitor of angiotensin-converting enzyme, captopril (SQ14,225; 2-D-methyl-3-mercaptopropranoyl-L-proline, dramatically lowered blood pressure both before and during dialysis. This agent holds promise as an alternate to bilateral nephrectomy in such patients.

Citing Articles

Hypertension in chronic kidney disease: navigating the evidence.

Tedla F, Brar A, Browne R, Brown C Int J Hypertens. 2011; 2011:132405.

PMID: 21747971 PMC: 3124254. DOI: 10.4061/2011/132405.

Hypertension in hemodialysis patients.

Rahman M, Smith M Curr Hypertens Rep. 2001; 3(6):496-502.

PMID: 11734096 DOI: 10.1007/s11906-001-0012-z.

Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Heel R, Brogden R, Speight T, Avery G Drugs. 1980; 20(6):409-52.

PMID: 7009133 DOI: 10.2165/00003495-198020060-00001.

Relief from malignant hypertension by treatment with captopril in a patient on maintenance hemodialysis.

WITZGALL H Klin Wochenschr. 1980; 58(17):871-3.

PMID: 7003235 DOI: 10.1007/BF01476998.

Absence of blood-pressure lowering effect of captopril in anephric patients.

Leslie B, Case D, Sullivan J, Vaughan Jr E Br Med J. 1980; 280(6221):1067-8.

PMID: 6992919 PMC: 1601200. DOI: 10.1136/bmj.280.6221.1067.